OncoMatch/Clinical Trials/NCT05999630
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
Is NCT05999630 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Artificial Tears Methylcellulose for nasolacrimal duct obstruction.
Treatment: Artificial Tears Methylcellulose — The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Thyroid Cancer
Prior therapy
Must have received: radioiodine
Radio-iodine therapy for thyroid cancer
Cannot have received: radiation therapy
Prior radiotherapy
Cannot have received: chemotherapy (5-fluorouracil, docetaxel)
Current or prior use of chemotherapy drugs (i.e. 5-fluorouracil, docetaxel)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanderbilt University Medical Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify